Targeted Medical Pharma Introduces New Dietary Supplement

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
Targeted Medical Pharma Introduces New Dietary Supplement Clearwayz™ for Healthy Sinus and Immune Function

Supporting the Sinus and Immune Systems' Anti-Inflammatory Processes

Targeted Medical Pharma, Inc. (OTCQB: TRGM) today announced the launch of Clearwayz, a dietary supplement specially formulated to support healthy sinus and immune function. Clearwayz is the first product in a line of dietary supplements being manufactured by AminoLabs, a division of Targeted Medical Pharma.

Clearwayz is the first oral supplement to utilize “Targeted Cellular Technology,” a patented molecular system used in our medical foods, which stimulates the rapid cellular uptake and utilization of nutrients. The proprietary formulation of polyphenols, nutrients and amino acids in Clearwayz provides the body with targeted nutrition to support the natural anti-inflammatory processes in the sinuses, as well as support a healthy immune response. Clearwayz can be purchased online at www.clearwayz.com, or by calling (888) 394-3439.

“Each ingredient in Clearwayz has been extensively researched for both safety and efficacy, and has established health benefits,” said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. “The use of polyphenols and amino acids to address inflammation and pulmonary issues is well regarded in the medical community. Clearwayz combines these ingredients into a proprietary blend which leverages our Targeted Cellular Technology platform to provide sustained sinus, immune and pulmonary support.”

About AminoLabs

Established in 2013, AminoLabs is a division of Targeted Medical Pharma Inc., which specializes in the research, development and commercialization of proprietary dietary supplements and novel delivery systems to increase uptake and improve ingredient efficacy.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I along with a line of proprietary dietary supplements.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.



Media Contacts:
Targeted Medical Pharma, Inc.
Marcus Charuvastra
(310) 474-9809
marcusch@ptlcentral.com
or
Investor Contacts:
ProActive Capital Group
Jeff Ramson
(646) 863-6893
ramson@proactivecapital.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

You Call The Play Inc. (YCTP) Leads with Integrity in Betting

Updated Category News Views 154

Understanding You Call The Play Inc. (YCTP)'s Initiative In an important move for the sports betting landscape, You Call The Play Inc. (YCTP) has recently unveiled a national licensing plan and a groundbreaking measure called the Safe Bet Overlay™. This initiative is designed to foster trust and transparency within an industry that continues to grow rapidly across the...

Continue Reading
Cash for Houses Pro Earns Stellar Reputation with 5-Star Reviews

Updated Category News Views 167

Cash for Houses Pro Achieves 5-Star Reviews Cash for Houses Pro is celebrating their recent success in receiving numerous 5-star reviews on Google for their service known as 'Sell Your House Fast In Tampa FL For Cash'. This recognition reflects the team's dedication to providing homeowners with a seamless and stress-free home selling experience. About Cash for Houses Pro...

Continue Reading
Pfizer's Potential Transformation Following Starboard Investment

Updated Category News Views 77

Pfizer's Revised Price Target and Market Standing Recently, CFRA, a prominent financial research firm, elevated its price target for Pfizer Inc. (NYSE:PFE) from $30.00 to $31.00 per share. This adjustment comes while maintaining a 'Hold' rating on the stock, suggesting a careful observation of its market performance. The current price target reflects a valuation based on...

Continue Reading
Equinox Gold's Impressive Q2 Results Spark Stock Surge Today

Updated Category News Views 103

Equinox Gold Delivers Strong Quarterly Performance Equinox Gold Corp. EQX has seen its shares rise significantly following the release of its second-quarter financial results, which exceeded market expectations. Investors reacted favorably, driving the stock up on Thursday. Financial Highlights from the Quarter In the latest quarterly report, Equinox Gold announced...

Continue Reading
Investor Insights on Alexandria Real Estate Equities' Legal Challenges

Updated Category News Views 219

Understanding the Alexandria Real Estate Equities, Inc. Lawsuit Investors have an important opportunity arising from a lawsuit against Alexandria Real Estate Equities, Inc. (NYSE: ARE). A national shareholder rights litigation firm has initiated a class action alleging the Company has violated various securities laws. This situation has caught the attention of many...

Continue Reading